ClinicalTrials.gg
Active, not recruitingNCT02600208Updated May 1, 2026

Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies With Alpha Beta TCell and B Cell Depletion Using the CliniMACS Device

A Phase 2 interventional study of CliniMACs in Hematologic Malignancies, sponsored by Julie-An M. Talano. Active, not recruiting at 1 site in United States. Open to female participants aged Up to 23 Years. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by Julie-An M. Talano · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
Up to 23 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 823 studies in Hematologic Neoplasms with a site in United States — 181 open to participants now, 277 under way, 12 of them phase 3. Hematologic Neoplasms · United States.

Planned enrollment
232nd of 660
60 · median 40
Started
2015
with 38 others
Phase 2
194 of 823
25 open now
Primary completion
2026-12
later than 76 of 274 live
Registered
334th of 823
by date

Among the 823 studies in Hematologic Neoplasms with a site in United States, this one is the 232nd largest by planned enrollment of the 660 interventional ones that give a count, is one of 39 that started in 2015, is one of 194 in phase 2, reaches primary completion later than 76 of the 274 other live ones, and was the 334th registered.

Hematologic Neoplasms

1,449 studies on the registry are indexed under Hematologic Neoplasms; 422 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

181 of the 823 studies in Hematologic Neoplasms with a site in United States are open now. Recruiting first, the newest first:

176 more — sign in →

All 181 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 313 Hematologic Neoplasms studies recruiting now, 209 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: Up to 23 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 823 studies in Hematologic Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This is a single arm pilot study for patients with hematologic malignancies with alternative donor sources receiving unrelated or partially matched related/Haploidentical mobilized peripheral stem cells (PSCs) using the CliniMACS system for Alpha Beta T cell depletion plus CD19+ B cell depletion to determine efficacy as determined by engraftment and GVHD, and one year leukemia free survival.

Read the detailed description

The purpose of this research study is to evaluate a new method of T cell depletion using the Miltenyi CliniMACS™ device for patients undergoing a peripheral stem cell transplant utilizing either a unrelated donor or partially matched/haploidentical related donor. This new method is called α/β (alpha/beta) T cell depletion and CD19+ B cell depletion. This pilot study will evaluate if this new method of T cell and B cell depletion is a more effective way of removing T cells thus reducing the risk of severe acute and chronic GVHD and result in a durable engraftment.

03

Conditions studied

  • Hematologic Malignancies
04

Who can participate

Ages eligible
Up to 23 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patient:

  1. Age. Patient age \< 23 years. Both genders and all races eligible.
  2. Disease eligibility

Leukemias/lymphomas:

  • Acute myeloid leukemia, primary or secondary
  • Disease status: remission or \<10% bone marrow blasts
  • Myelodysplasia
  • Acute lymphoblastic leukemia
  • Disease status: in hematologic remission
  • Chronic myelogenous leukemia:
  • Disease status: chronic phase, accelerated phase or blast crisis now in second chronic phase.
  • Mixed lineage or biphenotypic acute leukemia
  • Lymphoblastic lymphoma
  • Disease status: remission
  • Burkitt's lymphoma/leukemia:
  • Disease status: in remission

Exclusion criteria

Exclusion Criteria:

  • Patient

    1. Patients who do not meet disease, organ or infectious criteria.
    2. No suitable donor
05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Single Experimental Arm

    Alpha Beta T cell depletion is performed for all PBSC grafts using the CliniMACs device

    Device: CliniMACs

Interventions

  • DeviceCliniMACs

    Depletion of Alpha Beta T cells in the PBSC graft

    Also known as: Alpha/Beta T-Cell Depletion

06

What researchers measure

Primary outcomes

  1. Evaluate the engraftment of patients receiving unrelated donor or partially matched related donor peripheral stem cells that have T cell depleted and CD19+ B cell depleted using the CliniMACS device.

    Engraftment will be defined using the standard CIBMTR definition of ANC \>500 for the first of 3 consecutive days.

    Time frame: DAY 42

Secondary outcomes

  1. Assess the probability of one year leukemia free survival (LFS).

    Leukemia relapse is defined as presence of malignant cells in the blood or other body site after initiation of conditioning in a patient previously in remission.

    Time frame: 1 year

  2. Estimate the incidence and extent of acute and chronic graft vs. host disease.

    Acute GVHD will be graded using the standard Glucksberg grading system.

    Time frame: 1 year

  3. Assess the incidence treatment-related mortality (TRM).

    TRM is defined as death from non-disease related causes in the 100 days from stem cell infusion.

    Time frame: 1 year

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2015, a primary completion of Dec 2026 and a completion of Dec 2026. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2015
First posted
Nov 9, 2015
Start
Oct 2015
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02600208
Lead sponsor
Julie-An M. Talano
Collaborators
Miltenyi Biotec, Inc.
Responsible party
Julie-An M. Talano (Associate Professor - Department of Pediatrics - Division of Hematology/Oncology, Medical College of Wisconsin) — Sponsor-investigator
First posted
Nov 9, 2015
Start date
Oct 2015
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
May 1, 2026

Study contacts

Julie-An Talano, MD
principal investigator · Medical College of Wisconsin

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion